Myriad Genetics, Inc. announced new clinical data will be shared at the American Association for Cancer Research (AACR) Annual Meeting that highlights the performance of the Precise MRD test in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC). A podium presentation titled "Phase 2 trial of metastasis directed radiotherapy without systemic therapy (MRWS) for oligometastatic clear cell renal cell carcinoma ("ccRCC") and investigation of circulating tumor DNA (ctDNA) as a personalized biomarker" will be presented by Dr. Chad Tang, M.D., associate professor in the department of genetic radiation oncology at The University of Texas MD Anderson Cancer Center (MDACC) on April 28. The abstract presentation number is CT132.
MRWS offers substantial advantages for patients compared to more aggressive frontline systemic therapies; however, no clinically-utilized prognostic markers exist to identify patients who would benefit from such treatment de-escalation strategies1. In addition to the podium presentation by Dr. Tang, two Precise MRD posters will be on display on April 30 from 9:00am - 12:00pm in Section 10: Poster #6639: Optimized selection of tumor-informed MRD panels enhances sensitivity of ctDNA detection. Summary: Myriad's Precise MRD test is an ultrasensitive second-generation hybrid-capture-based tumor-informed assay that detects ctDNA in the plasma and uses a novel ranking algorithm to select up to 1,000 high- confidence targets based on tumor-specific and target-specific features to optimize panel design for residual disease detection.
Poster #6641: Inclusion of INDEL somatic variants in MRD panels improves confidence in ctDNA residual release detection. Summary: Including insertion/deletion (INDEL) mutations in the tumor-informed, patient-specific tumor panels used to monitor for MRD in patients with cancer increases the likelihood of detecting low abundance ctDNA and achieving high sensitivity at low tumor concentrations. Precise MRD is available for use in research studies pursued jointly by Myriad and academic or pharmaceutical investigators.
Myriad continues to develop its Precise MRD assay to meet the needs of patients with cancer, academic partners, and biopharma companies. The test is currently being evaluated in several high-impact studies and is performed at the company's laboratory facility in Salt Lake City.
